Zacks.com on MSN23m
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
BBC42s
BBC Inside Science
A weekly programme that illuminates the mysteries and challenges the controversies behind the science that's changing our world.